26 May Not All Biologics For Psoriasis Carry Same Risk Of Serious Infections

Posted at 20:39h in Author Interviews, Dermatology, JAMA by

MedicalResearch.com Interview with: Robert E Kalb, M.D. Clinical Professor of Dermatology State University of New York at Buffalo School of Medicine and Biomedical Sciences Buffalo Medical Group, P.C. Buffalo, NY 14221MedicalResearch.com Interview with:
Robert E Kalb, M.D.
Clinical Professor of Dermatology
State University of New York at Buffalo School of Medicine and Biomedical Sciences
Buffalo Medical Group, P.C.
Buffalo, NY 14221

Medical Research: What is the background for this study? What are the main findings?

Dr. Kalb: It’s important to evaluate the safety of biologics in the real world post-marketing setting, and in particular with respect to serious infections. We studied patients with psoriasis in the PSOLAR registry and evaluated the risk of various biologic therapies. We found that infliximab and adalimumab were associated with increased risk of serious infections when compared with non-biologic/non-methotrexate therapies, while ustekinumab and etanercept were not associated with increased risk.
Medical Research: What should clinicians and patients take away from your report?

Dr. Kalb: Not all biologics carry the same risk for serious infection even within a given class of therapy. Therapies with lower infection rates are a potential advantage in patients at a higher risk based on their comorbidities. One other point is that the risks of serious infections in this report are overall lower than the risk in two other disease states, rheumatoid arthritis and inflammatory bowel disease, which are often treated with biologic therapies.

Medical Research: What recommendations do you have for future research as a result of this study?

Dr. Kalb: A significant portion of patients with extensive psoriasis are ineligible for the clinical trials which are conducted for regulatory approval. These patients are treated in the real world with all the available systemic therapies. Long-term registry results such as these are important to understand the relative risk of all side effects in actual clinical practice.

Citation:

[wysija_form id=”3″]

 
MedicalResearch.com Interview with: Robert E Kalb, M.D., Clinical Professor of Dermatology, & State University of New York at Buffalo School of Medicine and Biomedical Sciences (2015). Not All Biologics For Psoriasis Carry Same Risk Of Serious Infections 

Last Updated on May 26, 2015 by Marie Benz MD FAAD

193
Tags:
,